Trial of Bezafibrate (Bezalip) in diabetic patients with primary hypertriglyceridaemia

Abstract

A trial of a new hyperlipidemic drug, Bezafibrate, was taken up in diabetic patients with primary hyperlipidemia. The study was done in 25 patients with primary hyperlipidemia. The study was done in 25 patients with type IV and 11 patients with type lib hyperlipidemia. Blood glucose was controlled prior to the trial with the drug. They took the tablets at a dose of 200 mg Lid. after food for 3 months and the lipid parameters were estimated each month. Significant improvement in triglycerides (TG) and cholesterol was seen in both groups of patients (P < 0.001) .The reduction in TG was seen even within a month and further improvement was observed in the subsequent months. The reduction in serum cholesterol was significant in Type lib patients. The LDL-cholesterol also decreased in these patients. No significant change was seen in HDL-cholesterol. The drug was well tolerated. The drug is thus found to be safe and effective for treatment of hyperlipidemia, especially hypertriglyceridemia.